Abelleyra Lastoria Diego Agustín, Keynes Sophie, Hughes Derralynn
Institute for Medical and Biomedical Education, St George's, University of London, London, SW17 0RE, UK.
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, University College London, London, NW3 2QG, UK.
Drugs. 2025 Feb;85(2):171-192. doi: 10.1007/s40265-025-02145-5. Epub 2025 Jan 18.
Lysosomal storage disorders (LSDs) are rare inherited metabolic disorders characterized by defects in the function of specific enzymes responsible for breaking down substrates within cellular organelles (lysosomes) essential for the processing of macromolecules. Undigested substrate accumulates within lysosomes, leading to cellular dysfunction, tissue damage, and clinical manifestations. Clinical features vary depending on the degree and type of enzyme deficiency, the type and extent of substrate accumulated, and the tissues affected. The heterogeneous nature of LSDs results in a variety of treatment approaches, which must be tailored to patient presentation and characteristics. The treatment landscape for LSDs is rapidly evolving. An up-to-date discussion of current evidence is required to provide clinicians with an appropriate overview of treatment options. Therefore, we aimed to review current and ongoing trials pertaining to the treatment of common LSDs.
溶酶体贮积症(LSDs)是罕见的遗传性代谢紊乱疾病,其特征是负责分解细胞内细胞器(溶酶体)中对大分子加工至关重要的底物的特定酶功能存在缺陷。未消化的底物在溶酶体内蓄积,导致细胞功能障碍、组织损伤和临床表现。临床特征因酶缺乏的程度和类型、蓄积底物的类型和程度以及受影响的组织而异。LSDs的异质性导致了多种治疗方法,这些方法必须根据患者的表现和特征进行调整。LSDs的治疗前景正在迅速发展。需要对当前证据进行最新讨论,以便为临床医生提供治疗选择的适当概述。因此,我们旨在综述与常见LSDs治疗相关的当前及正在进行的试验。